凱萊英(002821.SZ):是一家全球領先的新藥研發和生產CDMO一站式綜合服務商
格隆匯5月27日丨凱萊英(002821.SZ)在投資者互動平台表示,凱萊英是一家全球領先的新藥研發和生產 CDMO 一站式綜合服務商,服務於多家全球製藥業跨國企業和生物技術公司。公司承接的創新藥項目涉及很多熱門靶點的在研及已上市藥物。同時針對市場需求和潛力較大的產品管線,公司也戰略性的在推進產能提升。未來公司將依託深厚的技術創新底藴和高質量項目交付能力積極拓展市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.